

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

10 Jun 2026

### Evaluation of the efficacy of nanomisel curcumin in preventing and treating oral candidiasis of patients undergoing head and neck radiation therapy

#### Protocol summary

##### Study aim

Determination of the effect of nanomisel curcumin in preventing and treating oral candidiasis of patients undergoing head and neck radiation therapy

##### Design

A randomized, double blinded, clinical trial(phase III) for 40 patients has been designed. Randomization is performed using a computer-generated random number table.

##### Settings and conduct

This double-blind randomized clinical trial is conducted at Mashhad Dental School, Iran. Participants and care providers and assessing outcomes and the statistician are blinded to the type of drug because drugs are placed in similar seal envelope packs.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria: the minimum age of 18 years, presence of head and neck cancer, radiation dose of 50-70 Gy, at least 50% of patient's oral cavity in the field of radiation and patient satisfaction. Exclusion criteria included: previous history of radiation therapy, patient dissatisfaction, history of allergy to turmeric, , in case of any oral lesions or complication resulting from radiation therapy other than candidiasis and mucositis, use of systemic or topical antifungal drugs for any reason, pregnancy or breastfeeding periods in women under treatment, presence of local and systemic conditions predisposing for candidiasis, such as the application of inhaled and topical steroids, presence of hyperkeratosis, use of immunosuppressive drugs, history of systemic antibiotic usage over the previous 2 weeks, the presence of CFU above 400/ml in the first culture or clinical evidence based on the presence of oral candidiasis.

##### Intervention groups

The study group: nanocurcumin soft gel (containing 80 mg curcumin) are administrated orally once daily. The control group: placebo tablets are administrated orally

once daily.

##### Main outcome variables

Frequency of oral candidiasis

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20180416039318N3**

Registration date: **2018-06-02, 1397/03/12**

Registration timing: **registered\_while\_recruiting**

Last update: **2018-06-02, 1397/03/12**

Update count: **0**

##### Registration date

2018-06-02, 1397/03/12

##### Registrant information

##### Name

Ala Ghazi

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 51 3882 9501

##### Email address

ghazial@mums.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2018-05-22, 1397/03/01

##### Expected recruitment end date

2018-07-23, 1397/05/01

##### Actual recruitment start date

empty

**Actual recruitment end date**

empty

**Trial completion date**

empty

**Scientific title**

Evaluation of the efficacy of nanomisel curcumin in preventing and treating oral candidiasis of patients undergoing head and neck radiation therapy

**Public title**

Assessing the effect of nanomisel curcumin on prevention and treatment of nanomisel curcumin

**Purpose**

Treatment

**Inclusion/Exclusion criteria****Inclusion criteria:**

the minimum age of 18 years, presence of head and neck cancer, radiation dose of 50-70 Gy, at least 50% of patient's oral cavity in the field of radiation and patient satisfaction.

**Exclusion criteria:**

previous history of radiation therapy, patient dissatisfaction, history of allergy to turmeric, , in case of any oral lesions or complication resulting from radiation therapy other than candidiasis and mucositis, use of systemic or topical antifungal drugs for any reason, pregnancy or breastfeeding periods in women under treatment, presence of local and systemic conditions predisposing for candidiasis, such as the application of inhaled and topical steroids, presence of hyperkeratosis, use of immunosuppressive drugs, history of systemic antibiotic usage over the previous 2 weeks, the presence of CFU above 400/ml in the first culture or clinical evidence based on the presence of oral candidiasis.

**Age**

From **18 years** old

**Gender**

Both

**Phase**

2-3

**Groups that have been masked**

- Participant
- Care provider
- Outcome assessor
- Data analyser

**Sample size**

Target sample size: **40**

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

In this study, patients are randomly divided into two groups, namely the Study and Control groups. Randomization is performed using a computer-generated random number table.

**Blinding (investigator's opinion)**

Double blinded

**Blinding description**

In this study, the prepared medicine packs are the same for the two groups. Packages are coded from 1 to 40 by an individual outside the study. Packages are randomly

delivered to patients. The participants and care providers and assessing outcomes and statistician are blinded to type of drug.

**Placebo**

Used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Ethics committee of Mashhad University of Medical Sciences

**Street address**

Mashhad Dental School, Azadi Square, Vakilabad Blvd

**City**

Mashhad

**Province**

Razavi Khorasan

**Postal code**

911735984

**Approval date**

2015-09-09, 1394/06/18

**Ethics committee reference number**

IR.mums.sd.REC.1394.14

**Health conditions studied****1****Description of health condition studied**

Oral Candidiasis

**ICD-10 code**

B 37.0

**ICD-10 code description**

Candidal stomatitis/Oral thrush

**Primary outcomes****1****Description**

ccurrence of oral candidiasis

**Timepoint**

The first day of radiotherapy before radiation, every week until the end of the study

**Method of measurement**

Clinical examinations of oral lesion

**2****Description**

Candidate colony count in ml (colony forming unit = CFU)

**Timepoint**

before the study, in the third week and the final week of radiotherapy

**Method of measurement**

Cultivation of oral lesions

**Secondary outcomes****1****Description**

type of oral Candidiasis

**Timepoint**

before the study, in the third week and the final week of radiotherapy

**Method of measurement**

germ tube test and cultivation of oral lesions

**Intervention groups****1****Description**

Intervention group: nanocurcumin soft gel (containing 80 mg curcumin) are administrated orally once daily.

**Category**

Treatment - Drugs

**2****Description**

Control group: The control group: placebo tablets are administrated orally once daily.

**Category**

Placebo

**Recruitment centers****1****Recruitment center****Name of recruitment center**

مرکز تخصصی رادیوتراپی و آنکولوژی رضا

**Full name of responsible person**

Dr Zahra Delavarian

**Street address**

Misaq 19, Misaq Blvd, Vakil abad Blvd, Mashhad, Iran

**City**

Mashhad

**Province**

Razavi Khorasan

**Postal code**

9177948959

**Phone**

+98 51 3522 4472

**Email**

delavarianz@mums.ac.ir

**Sponsors / Funding sources****1****Sponsor****Name of organization / entity**

Mashhad University of Medical Sciences

**Full name of responsible person**

Dr Mohsen Tafaghodi

**Street address**

Mashhad University of Medical Sciences, Daneshgah St.

**City**

mashhad

**Province**

Razavi Khorasan

**Postal code**

91388-13944

**Phone**

+98 51 3882 3255

**Email**

tafaghodiM@mums.ac.ir

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Mashhad University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

empty

**Country of origin****Type of organization providing the funding**

Academic

**Person responsible for general inquiries****Contact****Name of organization / entity**

Mashhad University of Medical Sciences

**Full name of responsible person**

Sedigheh Modarres Mousavy

**Position**

Assistant Professor

**Latest degree**

Specialist

**Other areas of specialty/work**

Dentistry

**Street address**

Mashhad Dental School, Azadi Square, Vakilabad Blvd

**City**

Mashhad

**Province**

Razavi Khorasan

**Postal code**

9177948959

**Phone**

+98 51 3882 9501

**Email**

ModarresMS921@mums.ac.ir

## Person responsible for scientific inquiries

### Contact

**Name of organization / entity**

Mashhad University of Medical Sciences

**Full name of responsible person**

Zahra Delavarian

**Position**

Professor

**Latest degree**

Specialist

**Other areas of specialty/work**

Dentistry

**Street address**

Mashhad Dental School, Azadi Square, Vakilabad Blvd

**City**

Mashhad

**Province**

Razavi Khorasan

**Postal code**

9177948959

**Phone**

+98 51 3882 9501

**Email**

delavarianz@mums.ac.ir

## Person responsible for updating data

### Contact

**Name of organization / entity**

Mashhad University of Medical Sciences

**Full name of responsible person**

Ala Ghazi

**Position**

Assistant Professor

**Latest degree**

Specialist

**Other areas of specialty/work**

Dentistry

**Street address**

Mashhad Dental School, Azadi Square, Vakilabad Blvd

**City**

Mashhad

**Province**

Razavi Khorasan

**Postal code**

9177948959

**Phone**

+98 51 3882 9501

**Email**

ghazial@mums.ac.ir

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

**Study Protocol**

Yes - There is a plan to make this available

**Statistical Analysis Plan**

Yes - There is a plan to make this available

**Informed Consent Form**

No - There is not a plan to make this available

**Clinical Study Report**

Yes - There is a plan to make this available

**Analytic Code**

Not applicable

**Data Dictionary**

Not applicable

**Title and more details about the data/document**

Some data including demographic properties, signs and symptoms

**When the data will become available and for how long**

Two months after article publication.

**To whom data/document is available**

Academic researchers

**Under which criteria data/document could be used**

It is permitted to use the data in other studies with reference.

**From where data/document is obtainable**

Dr.Sedigheh Modarres Mousavy,  
ModarresMS921@mums.ac.ir

**What processes are involved for a request to access data/document**

Sending email to authors. the authors will send data via email during 4 weeks

**Comments**